Ivarmacitinib vs steroids for mild-to-moderate lupus
Treatments studied
Part of Immune system & allergy clinical trials.
This study compares a new pill (ivarmacitinib) to standard steroid treatment for people with mild-to-moderate lupus. It aims to see if the new drug can better control symptoms like joint pain and skin rashes while possibly reducing steroid side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a doctor-confirmed diagnosis of lupus (SLE).
- Your lupus symptoms should be mild to moderate, with a score between 4 and 12 on a standard lupus activity test.
- You should have active joint or skin symptoms (like rashes or mouth sores) at the time of screening.
- You must be on a stable dose of your current lupus medicines (like steroids, hydroxychloroquine, or an immunosuppressant) for at least 4 weeks before joining.
- You cannot have severe lupus complications like active kidney disease, nervous system problems, or low blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This study tests a new pill, ivarmacitinib, for people with moderate-to-severe rheumatoid arthritis who have not gotten enough relief from standard treatments. It aims to reduce joint pain and swelling and improve daily life.
This trial tests an investigational drug, ivarmacitinib, to see if it can reduce inflammation and pain in people with polymyalgia rheumatica and help them avoid using steroids. The drug works by blocking certain immune system signals that cause joint and muscle stiffness.
This trial tests a new oral medication called Ivarmacitinib for people with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it helps reduce symptoms and improve skin condition.
This study tests a pill called Ivarmacitinib (a JAK inhibitor) for people with advanced solid tumors who had to stop immunotherapy because of side effects. The drug aims to calm the immune system and may help you restart cancer treatment.
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.